|  |
| --- |
| **Pharmacy and Therapeutics Committee** Virtual MeetingMay 23, 202312:00 PM - 5:00 PM |
| [**Zoom Meeting Registration**](https://ahcccs.zoom.us/webinar/register/WN_ZfWV5RuSR7iaiHktD6OzKA?_x_zm_rtaid=xhCiZxU6RvikOxapEx01bw.1683734906823.f74b144373e9c862ef10db92c363e3ce&_x_zm_rhtaid=508#/registration) |
| **Time** | **Topic** |
| **12:00 PM** | **Welcome and Introductions:** Suzanne Berman, RPH, AHCCCS Pharmacy Director |
| **12:10 PM** | **Minutes Review and Vote - P&T January 25, 2023:** Suzanne Berman, RPH, AHCCCS Pharmacy Director |
| **12:15 PM** | **Nineteen Supplemental Rebate Drug Class Reviews:** Clinical review by Hind Douiki, PharmD, Magellan1. **Analgesics Agents**
	1. Public Testimony: None
2. **Antibiotics - Inhaled**
	1. Public Testimony: None
3. **Anticoagulants**
	1. Public Testimony: None
4. **Antimigraine - CGRPs**
	1. Oral Public Testimony:
		1. Rochelle Yang
	2. Written Public Testimony: None
5. **Antipsychotics - Atypical Long-Acting Injectables**
	1. Oral Public Testimony:
		1. Kenneth Berry
	2. Written Public Testimony:
		1. John Sarris
		2. Kristin Sabetta – Antipsychotics in general
		3. Miguel Tosado Rivera – Antipsychotics in general
6. **Antipsychotics - Oral Atypicals - 2nd Generation**
	1. Oral Public Testimony:
		1. Laura Anderson
		2. Kenneth Berry
		3. Ana McNabb
		4. Heather Fremi
	2. Written Public Testimony
		1. Devin Wengert
		2. James Reed
		3. Kristin Sabetta - Antipsychotics in general
		4. Miguel Tosado Rivera – Antipsychotics in general
7. **COPD**
	1. Public Testimony: None
8. **Cytokine and CAM Antagonists**
	1. Oral Public Testimony:
		1. Melissa Sommers
9. **Epinephrine - Self-Injected**
	1. Public Testimony: None
10. **Glucagon**
	1. Oral Public Testimony:
		1. Dena Bondugji
		2. Rachel Shubitz
11. **Glucocorticoids - Inhaled**
	1. Public Testimony: None
12. **Growth Hormone**
	1. Public Testimony: None
13. **Hepatitis C Agents**
	1. Public Testimony: None
14. **Hypoglycemics - Incretin Mimetics**
	1. Oral Public Testimony: None
	2. Written Public Testimony: None
15. **Hypoglycemics - Insulin and Related Agents**
	1. Public Testimony: None
16. **Opioid Dependence Treatments**
	1. Oral Public Testimony:
		1. Kenneth Berry
		2. Jake Nichols – Testimony for 2 drugs
	2. Written Public Testimony: None
17. **Pancreatic Enzymes**
	1. Public Testimony: None
18. **Progestational Agents**
	1. Public Testimony: None
19. **Stimulants and Related Agents**
	1. Public Testimony: None
 |
| **2:45 PM** | **New Drug Reviews: Hind Douiki,** PharmD, Magellan1. **Joenja**
	1. **Public Testimony – Brian Hartline**
 |
| **3:00 PM**  | **Break & Executive Session:** Kristen Haloski**,** PharmD, AAHIVP, Magellan |
| **4:15 PM** | **Public Therapeutic Class Votes:** Hind Douiki, PharmD, Magellan |
| **4:45 PM** | **Biosimilar Update: Suzi Berman**1. **Amjevita (Adalimumab-ATTO)**
 |
| **4:50 PM** | **Meeting Adjournment**Future Meeting Dates: October 25, 2023, January 24, 2024 |